View in Other Languages

Regeneus Ltd

ASX:RGS ISIN:AU000000RGS6

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address significant unmet medical needs in the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain and dermatology.

       

News

Regeneus Ltd (ASX:RGS) Appoints International Directors for Global Growth

🕔4/29/2019 8:48:54 AM 1818

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce the appointment of John Chiplin, PhD and Alan W. Dunton, M.D. to its Board of Directors, effective 29 April 2019 as independent, Non-Executive Directors.

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Results

🕔4/11/2019 10:48:52 AM 1985

Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 31 March, 2019.

Read Full Article

Regeneus Ltd (ASX:RGS) Half-Year Report

🕔3/1/2019 8:08:49 AM 2523

Regeneus (ASX:RGS) is an ASX-listed clinical-stage regenerative medicine company developing a portfolio of novel cell-based therapies targeting significant unmet medical needs in human and animal health, with an initial focus on osteoarthritis, neuropathic pain and dermatology. The Company's product pipeline is underpinned by proprietary stem cell technologies.

Read Full Article

Regeneus Ltd (ASX:RGS) Directors Provide $2.5M Loan to Extend Funding Runway

🕔2/28/2019 1:27:23 PM 2544

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce that its Board of Directors have put in place loan funding of $2.5m to extend the Company's funding runway for the development and licensing of its clinical assets.

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Report

🕔1/30/2019 3:51:34 PM 2508

Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 31 December 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) New CEO Appointed to Accelerate Global Growth

🕔1/23/2019 9:48:46 AM 3227

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce that it has appointed Leo Lee as the company's new Chief Executive Officer and member of Board of Directors, effective immediately. Leo will succeed the outgoing CEO, John Martin, after 10 years of valuable service to the company.

Read Full Article

Regeneus Ltd (ASX:RGS) Chinese Patent Granted for Biomarkers for Stem Cell Therapy

🕔12/3/2018 9:34:26 AM 3960

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce the State Intellectual Property Office of China has granted the Company a patent for the use of biomarkers to monitor disease progression in a patient having mesenchymal cell therapy for inflammatory conditions.

Read Full Article

Regeneus Ltd (ASX:RGS) Chairman's Address to Shareholders

🕔11/22/2018 2:06:22 PM 4747

Regeneus Ltd (ASX:RGS) provides the Company's Chairman Address to Shareholders.

Read Full Article

Regeneus Ltd (ASX:RGS) Presentation for AusBiotech 2018

🕔10/31/2018 4:26:22 PM 3344

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce John Martin, CEO, will present at the AusBiotech 2018 Conference today.

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Results for the Period Ended 30 September 2018

🕔10/24/2018 9:08:53 AM 3104

Regeneus Ltd (ASX:RGS) provides the Company's quarterly results for the period ended 30 September 2018.

Read Full Article
###

119,167 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 115) (Last 30 Days: 550) (Since Published: 53646) 

Markets ASX:RGS

Company Data

    Headquarters
  • Ground floor, 25 Bridge Street
    Pymble NSW 2073
    Australia
  • Telephone
  • +61-2-9499-8010 
  • Fax
  • +61-2-9499-8020 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.regeneus.com.au
  • E:
  • info@regeneus.com.au

Presentations

Research Report

Quarterly Report

Social Media